Symposium
Covalent Inhibitor Drug Discovery & Development: Biology, Chemistry, PK, Safety and Case Studies (Jointly with Bay Area PKPD Network)
Speakers:
Tom Baillie (Univ Washington), Jack Taunton (UCSF), Joachim Rudolph (Genentech), Dane Karr (Nurix), Zhengping Wang (Revolution Medicine), Shirin Kapur (ex-Onyx), Leah Schutt- (Genentech), Betty Chang (ex-Pharmacyclics)
Organizers:
Xu (Richard) Zang, PhD (Genentech)
Date:
2019-02-07
Time:
8:45-17:00 Pacific Time
Registration fee:
(USD): Regular: $195; Academic: $125; Students & Unemployed: $35
Location:
Crowne Plaza, Foster City, CA
Major Sponsor:
Vendor show vendors registered to date:
(20)AIT Bioscience; Alturas Analytics; Averica Discovery Services; BioreclamationIVT; Celerion; cgenetool; CMIC Inc.; Cytovier LLC; Intertek; MagArray; MedChemExpress; Medpace; MicroConstants; MRIGlobal; Mycenax; Nucleo Life Sciences; Sekisui XenoTech, LLC; Selvita Inc.; Seventh Wave; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2019-02-04
(it will close sooner if the seating cap is reached)
About the Topic
In recent years, there has been a renewed interest in drug development of covalent inhibitors. Several of these inhibitors have been approved by the FDA and EMA and more covalent inhibitors are in early and late stage development. Covalent inhibitors can have superior affinity towards target proteins compared to their non-covalent counterparts, potentially resulting in improved therapeutic benefit. This symposium will cover a wide range topics pertaining to covalent inhibitors discovery and development
Key Topics:
- Targeted Covalent Inhibitors for Drug Design – Tom Baillie (UW)
- Kinetic selectivity with lysine-targeted kinase inhibitors – Jack Taunton (UCSF)
- Covalent modification in drug discovery - a chemist's perspective – Joachim Rudolph (Genentech)
- Preclinical challenges for reversible covalent inhibitors – Dane Karr (Principia)
- Development of covalent proteosome inhibitors: DMPK and clinical pharmacology perspectives – Zhengping Wang (Revolution Medicine)
- Benchmark for Selective Sustained Proteasome Inhibition – Shirin Kapur (Cortexyme)
- Safety Considerations for Covalent Inhibitors - Leah Schutt- (Genentech)
- From bench to bedside: The story of a first-in-class covalent BTK inhibitor ibrutinib– Betty Chang
Agenda:
8:45-8:55 Welcome and overview - Richard Zang / Shichang Miao
8:55-9:40 Targeted Covalent Inhibitors for Drug Design - Tom Baillie
9:40-10:25 Kinetic selectivity with lysine-targeted kinase inhibitors - Jack Taunton
10:25-10:35 Major Sponsor's Presentation
10:35-10:50 Break
10:50-11:35 Covalent modification in drug discovery - a chemist's perspective - Joachim Rudolph
11:35-12:20 Safety Considerations for Covalent Inhibitors - Leah Schutt
12:20-13:20 Lunch
13:20-14:05 Preclinical challenges for reversible covalent inhibitors - Dane Karr
14:05-14:50 From bench to beside: The story of a first-in-class covalent BTK inhibitor ibrutinib - Betty Chang
14:50-15:00 Major Sponsor's Presentation
15:00-15:15 Break
15:15-16:00 Benchmark for Selective Sustained Proteasome Inhibition - Shirin Kapur
16:00-16:45 Development of covalent proteasome inhibitors: DMPK and clinical pharmacology perspectives - Zhengping Wang
16:45-17:15 Panel Discussion
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
|
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Online Workshop] Career Transition for Research Scientists
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|